Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1GATA2 Deficiency 1Carcinoma, Neuroendocrine 1

Interventions

ruxolitinib 8fludarabine phosphate 3bomedemstat 3Whole-Body Irradiation 3Tacrolimus 3Specimen Handling 3Mycophenolic Acid 3Cyclophosphamide 3Biopsy 3fludarabine 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Melphalan 2Injections 2Busulfan 2venetoclax 1veliparib 1piperine 1pevonedistat 1iadademstat 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1anagrelide 1X-Rays 1Valganciclovir 1Transplantation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × iadademstat × 1 year × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡